Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases.
Article Details
- CitationCopy to clipboard
Mayence A, Vanden Eynde JJ
Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases.
Pharmaceuticals (Basel). 2019 Mar 12;12(1). pii: ph12010037. doi: 10.3390/ph12010037.
- PubMed ID
- 30871014 [ View in PubMed]
- Abstract
In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Baricitinib Non-receptor tyrosine-protein kinase TYK2 Protein Humans UnknownInhibitorDetails Baricitinib Tyrosine-protein kinase JAK1 Protein Humans YesInhibitorDetails Baricitinib Tyrosine-protein kinase JAK2 Protein Humans YesInhibitorDetails Baricitinib Tyrosine-protein kinase JAK3 Protein Humans YesInhibitorDetails